Alcide Corporation – Trademark Portfolio
Entity Type: 03
Alcide Corporation holds 32 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 26 filings in this category. The portfolio also extends into Class 1 (Chemicals) across 6 Nice Classification classes. Currently, 6 trademarks are registered. Notable registered marks include 4XLA, EXSPOR, SANOVA, and UDDERGOLD. The owner is based in Westport, CT.
125 Main St.
Westport, CT 06880
Showing of trademarks Trademarks
Trademark Classifications
Alcide Corporation's trademark portfolio spans 6 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Bleaching preparations and other substances for laundry use; cleaning, polishing, scouring
Frequently Asked Questions
How many trademarks does Alcide Corporation have?
Alcide Corporation has 32 U.S. trademarks filed with the USPTO. Of these, 6 registered, 7 abandoned, 19 cancelled.
What trademark classes does Alcide Corporation file in?
Alcide Corporation files trademarks across 6 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 1 (Chemicals), Class 3 (Cosmetics & Cleaning), Class 25 (Clothing), Class 14 (Jewelry). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Alcide Corporation's most well-known trademarks?
Alcide Corporation's registered trademark portfolio includes well-known marks such as 4XLA, EXSPOR, SANOVA, and UDDERGOLD. These are among 6 currently registered trademarks in the portfolio.
What is Alcide Corporation's trademark registration success rate?
Alcide Corporation has a 19% trademark registration rate, with 6 out of 32 resolved applications resulting in successful registration. Currently, 0 applications are pending review.